Get the Stockscreener App
4.68
2.90%
-0.14
After Hours:
4.87
0.19
+4.06%
Aquestive Therapeutics Inc stock is traded at $4.68, with a volume of 1.91M.
It is down -2.90% in the last 24 hours and down -7.87% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.82
Open:
$4.82
24h Volume:
1.91M
Relative Volume:
0.69
Market Cap:
$587.39M
Revenue:
$50.27M
Net Income/Loss:
$-68.91M
P/E Ratio:
-7.7612
EPS:
-0.603
Net Cash Flow:
$-44.32M
1W Performance:
+1.52%
1M Performance:
-7.87%
6M Performance:
+11.16%
1Y Performance:
-11.03%
1-Day Range:
$4.66
$4.86
1-Week Range:
$4.56
$5.105
52-Week Range:
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.68 | 587.39M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics posts investor presentation; NDA resubmission for Anaphylm, $98.5M cash - tradingview.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect - accessnewswire.com
Anaphylm returns to FDA after Aquestive addresses usability, PK concerns - AllSci
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Aquestive Therapeutics CEO Barber Daniel Offloads 25,000 Shares at $4.82 Each - Kalkine Media
Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment - Benzinga
Aquestive resubmits Anaphylm FDA application for anaphylaxis - grafa.com
Aquestive resubmits drug application for anaphylaxis treatment By Investing.com - Investing.com Australia
Aquestive resubmits drug application for anaphylaxis treatment - Investing.com
Aquestive Therapeutics Resubmits NDA for Anaphylm Sublingual Film After Positive Human Factors and PK Study Results - Quiver Quantitative
Allergy film that cuts dosing time resubmitted by Aquestive (NASDAQ: AQST) - Stock Titan
Aquestive Therapeutics Announces Resubmission of New Drug - globenewswire.com
Aquestive Therapeutics CEO Barber sells $120,487 in shares By Investing.com - Investing.com Nigeria
Aquestive Therapeutics CEO Barber sells $120,487 in shares - Investing.com
Aquestive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Barber Daniel - Moomoo
Aquestive Therapeutics (AQST) CEO sells 25,000 shares in preset plan trade - Stock Titan
Aquestive Therapeutics CCO Executes 8,750 Share Sale Following Option Exercise Under 10b5-1 Plan - Kalkine Media
Aquestive (NASDAQ: AQST) CCO sells 8,750 shares after exercising options - Stock Titan
Aquestive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Korczynski Sherry - Moomoo
Cantor Fitzgerald reiterates Aquestive stock Overweight on Anaphylm profile By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) insider adds 2,293 shares - Stock Titan
Aquestive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Boyd Peter E. - Moomoo
Aquestive at cantor healthcare conference: anaphylm launch nears By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) CEO boosts stake with warrant exercise - Stock Titan
Aquestive Therapeutics (AQST) COO adds shares via warrant exercise - Stock Titan
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire
AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - accessnewswire.com
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Blue Owl Capital Holdings LP Makes New $3.92 Million Investment in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress - TipRanks
Latash Investments LLC Acquires New Holdings in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive reports study results for Anaphylm allergy treatment By Investing.com - Investing.com Nigeria
Aquestive Therapeutics (NASDAQ:AQST) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Aquestive Therapeutics: Potential Catalyst On The Horizon (NASDAQ:AQST) - Seeking Alpha
Aquestive (AQST) Q2 2026 Earnings Call Transcript - AOL.com
Aquestive Therapeutics CEO Daniel Barber Sells 25,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Aquestive (AQST) Closing Snapshot: Records a 0.70% Increase to $4.32 in the Current Update; Technical Focus - Vinanet
Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $107,168 - Bitget
Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan - Stock Titan
Aquestive Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed - Stock Titan
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):